Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives
Launched by M.D. ANDERSON CANCER CENTER · Feb 4, 2020
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
PRIMARY OBJECTIVES:
I. Identify and explore factors influencing the communication of genetic testing results from probands (patients with confirmed hereditary cancer predisposition syndrome) to their first-degree relatives. (Step 1) II. Identify and explore factors influencing decision making and pursuit of cascade testing among first-degree relatives of probands. (Step 1) III. Estimate the uptake of cascade testing by first-degree relatives of probands at a safety-net hospital and the uptake of cascade testing by first-degree relatives of probands at a comprehensive cancer center. (Step 2...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • STEP 1 (PROBANDS): Speaks and/or reads English or Spanish
- • STEP 1 (PROBANDS): Currently receiving diagnostic, treatment, or follow-up care in the outpatient gynecologic oncology and medical oncology clinics at LBJ
- • STEP 1 (PROBANDS): Has completed genetic counseling, with pedigree available in the medical record (LBJ)
- • STEP 1 (PROBANDS): Diagnosed with female-breast, ovarian, fallopian tube, primary peritoneal, endometrial cancer on or after January 1, 2014
- • STEP 1 (PROBANDS): Has a confirmed deleterious or suspected deleterious (pathogenic) variant in a hereditary gynecologic or breast cancer predisposition gene (including BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, BRIP1, PALB2, RAD51C, RAD51D, STK11, DICER1, SMARCA4, ATM, CHEK2, PTEN, TP53, CDH1, BARD1)
- • STEP 1 (FIRST-DEGREE RELATIVE \[FDR\]): Speaks and/or reads English or Spanish
- • STEP 1 (FDR): Is a first-degree relative of proband (son, daughter, full-brother, full-sister, mother, father)
- • STEP 1 (FDR): Is present with proband at time of recruitment, or can be contacted by telephone via a United States (U.S.) telephone number
- • STEP 1 (FDR): Is aware of proband's genetic testing result/mutation status, per proband report
- • STEP 2 (PROBANDS): Speaks or reads English or Spanish
- • STEP 2 (PROBANDS): Currently receives diagnostic, treatment, or follow-up care for female-breast cancer in the outpatient medical oncology clinics at LBJ; or currently receives diagnostic, treatment, or follow-up care for ovarian, fallopian tube, primary peritoneal or endometrial cancer in the outpatient gynecologic oncology clinic at LBJ or the outpatient gynecologic oncology clinic at The University of Texas MD Anderson Cancer Center (MD Anderson)
- • STEP 2 (PROBANDS): Diagnosed with eligible cancer on or after January 1, 2014
- • STEP 2 (PROBANDS): Has completed genetic counseling, with a pedigree available in the medical record (LBJ) or internal clinical and research database (progeny at MD Anderson)
- • STEP 2 (PROBANDS): Has a confirmed deleterious or suspected deleterious (pathogenic) variant in a hereditary gynecologic or breast cancer predisposition gene (including BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, BRIP1, PALB2, RAD51C, RAD51D, STK11, DICER1, SMARCA4, ATM, CHEK2, PTEN, TP53, CDH1, BARD1)
- • STEP 2 (FDR): Speak and/or reads English or Spanish
- • STEP 2 (FDR): First-degree relative of proband (son, daughter, full-brother, full-sister, mother, father)
- • STEP 2 (FDR): Is present with proband at time of recruitment, or can be contacted by telephone via a U.S. telephone number
- • STEP 2 (FDR): Is aware of proband's genetic testing result/mutation status, per proband report
- Exclusion Criteria:
- • STEP 1 (PROBANDS): No longer receives outpatient care at LBJ
- • STEP 1 (PROBANDS): Has a negative genetic testing result, a result identifying only a variant of uncertain significance, or results and pedigree that cannot be confirmed in the electronic medical record
- • STEP 1 (PROBANDS): Is unwilling or unable to provide informed consent
- • STEP 1 (FIRST-DEGREE RELATIVE \[FDR\]): Unwilling or unable to provide informed consent
- • STEP 2 (PROBANDS): No longer receives outpatient care at LBJ or MD Anderson
- • STEP 2 (PROBANDS): Has a negative genetic testing result, a result identifying only a variant of uncertain significance, or results and pedigree that cannot be confirmed in the electronic medical record
- • STEP 2 (PROBANDS): Unwilling or unable to provide informed consent
- • STEP 2 (PROBANDS): Participated in step 1 interviews
- • STEP 2 (FDR): Unwilling or unable to provide informed consent
- • STEP 2 (FDR): Reports no knowledge of proband's genetic testing status
- • STEP 2 (FDR): Participated in step 1 interviews
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Birmingham, Alabama, United States
Patients applied
Trial Officials
Jose A Rauh-Hain
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials